Adherex (ADH) Announces 2 Presentations of ADH-1 Data at Annual Meeting

April 17, 2007 8:37 AM EDT

Adherex Technologies Inc. (AMEX: ADH) announced that the Company will be presenting preclinical data on ADH-1 in combination with chemotherapy in a poster presentation at the 2007 Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

This study explored in vitro and in vivo anti-tumor activity of ADH-1 alone, paclitaxel alone and ADH-1 and paclitaxel in combination using ovarian cell lines and ovarian cancer xenograft animal models. In vitro, ADH-1 was found to have a synergistic effect with paclitaxel in the ovarian cell lines. In vivo, the combination of ADH-1 and paclitaxel was found to have anti-tumor activity significantly superior to the untreated group and groups treated with single-agent ADH-1 alone or paclitaxel alone.

Adherex is currently conducting two clinical trials of ADH-1 in combination with chemotherapy. The first, which began in October 2006, is exploring ADH-1 in combination with three different anti-cancer chemotherapies (docetaxel, carboplatin and capecitabine). The second, which began in March 2007, is exploring the combination of systemic ADH-1 plus isolated limb infusion melphalan for the treatment of melanoma.

Related Categories

FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?